Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors: a retrospective study by the EBMT Chronic Malignancies Working Party
The prognosis of patients with blast crisis (BC) chronic myeloid leukemia (CML) is still dismal. Allogeneic stem cell transplantation represents the only curative treatment option, but data on transplant outcomes are scarce. We therefore conducted a retrospective, registry-based study of adult patie...
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
1 July 2019
|
| In: |
Biology of blood and marrow transplantation
Year: 2019, Jahrgang: 25, Heft: 10, Pages: 2008-2016 |
| ISSN: | 1523-6536 |
| DOI: | 10.1016/j.bbmt.2019.06.028 |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1016/j.bbmt.2019.06.028 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1083879119304124 
|
| Verfasserangaben: | Aleksandar Radujkovic, Sascha Dietrich, Henric-Jan Blok, Arnon Nagler, Francis Ayuk, Jürgen Finke, Johanna Tischer, Jiri Mayer, Yener Koc, Federica Sorà, Jakob Passweg, Jenny L. Byrne, Pavel Jindra, Joan Hendrik Veelken, Gerard Socié, Johan Maertens, Nicolaas Schaap, Michael Stadler, Maija Itälä-Remes, Eleni Tholouli, Mutlu Arat, Vanderson Rocha, Per Ljungman, Ibrahim Yakoub-Agha, Nicolaus Kröger, Yves Chalandon |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1687319804 | ||
| 003 | DE-627 | ||
| 005 | 20230427090128.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 200114s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbmt.2019.06.028 |2 doi | |
| 035 | |a (DE-627)1687319804 | ||
| 035 | |a (DE-599)KXP1687319804 | ||
| 035 | |a (OCoLC)1341297989 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Radujković, Aleksandar |d 1980- |e VerfasserIn |0 (DE-588)132951320 |0 (DE-627)529183536 |0 (DE-576)299523721 |4 aut | |
| 245 | 1 | 0 | |a Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors |b a retrospective study by the EBMT Chronic Malignancies Working Party |c Aleksandar Radujkovic, Sascha Dietrich, Henric-Jan Blok, Arnon Nagler, Francis Ayuk, Jürgen Finke, Johanna Tischer, Jiri Mayer, Yener Koc, Federica Sorà, Jakob Passweg, Jenny L. Byrne, Pavel Jindra, Joan Hendrik Veelken, Gerard Socié, Johan Maertens, Nicolaas Schaap, Michael Stadler, Maija Itälä-Remes, Eleni Tholouli, Mutlu Arat, Vanderson Rocha, Per Ljungman, Ibrahim Yakoub-Agha, Nicolaus Kröger, Yves Chalandon |
| 264 | 1 | |c 1 July 2019 | |
| 300 | |a 9 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 14.01.2020 | ||
| 520 | |a The prognosis of patients with blast crisis (BC) chronic myeloid leukemia (CML) is still dismal. Allogeneic stem cell transplantation represents the only curative treatment option, but data on transplant outcomes are scarce. We therefore conducted a retrospective, registry-based study of adult patients allografted for BC CML, focusing on patients with active disease at transplant and pretransplant prognostic factors. One hundred seventy patients allografted for BC CML after tyrosine kinase inhibitor pretreatment between 2004 and 2016 were analyzed. Before transplant, 95 patients were in remission, whereas 75 patients had active BC. In multivariable analysis of the entire cohort, active BC at transplant was the strongest factor associated with decreased overall survival (hazrd ratio, 1.87; P=.010) and shorter leukemia-free survival (LFS; hazard ratio, 1.69; P=.017). For patients with BC in remission at transplant, advanced age (≥45 years), lower performance status (≤80%), longer interval from diagnosis BC to transplant (>12 months), myeloablative conditioning, and unrelated donor (UD) transplant were risk factors for inferior survival. In patients with active BC, only UD transplant was significantly associated with prolonged LFS and trended toward improved overall survival. In summary, survival of patients allografted for BC CML was strongly dependent on pretransplant remission status. In patients with remission of BC, conventional prognostic factors remained the major determinants of outcome, whereas in those with active BC at transplant, UD transplant was associated with prolonged LFS in our study. | ||
| 650 | 4 | |a Allogeneic stem cell transplantation | |
| 650 | 4 | |a Blast crisisf per raduikovic, a? | |
| 650 | 4 | |a Chronic myeloid leukemia | |
| 650 | 4 | |a Outcome | |
| 650 | 4 | |a Tyrosine kinase inhibitor | |
| 700 | 1 | |a Dietrich, Sascha |d 1979- |e VerfasserIn |0 (DE-588)136406300 |0 (DE-627)694354635 |0 (DE-576)301003408 |4 aut | |
| 700 | 1 | |a Blok, Henric-Jan |e VerfasserIn |0 (DE-588)1202814336 |0 (DE-627)1687319103 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biology of blood and marrow transplantation |d [Erscheinungsort nicht ermittelbar] : Elsevier Health Sciences, 1998 |g 25(2019), 10, Seite 2008-2016 |h Online-Ressource |w (DE-627)334374782 |w (DE-600)2057605-5 |w (DE-576)118352229 |x 1523-6536 |7 nnas |a Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors a retrospective study by the EBMT Chronic Malignancies Working Party |
| 773 | 1 | 8 | |g volume:25 |g year:2019 |g number:10 |g pages:2008-2016 |g extent:9 |a Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors a retrospective study by the EBMT Chronic Malignancies Working Party |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.bbmt.2019.06.028 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S1083879119304124 |x Verlag |x Resolving-System |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20200114 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 136406300 |a Dietrich, Sascha |m 136406300:Dietrich, Sascha |d 910000 |d 910100 |e 910000PD136406300 |e 910100PD136406300 |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 132951320 |a Radujković, Aleksandar |m 132951320:Radujković, Aleksandar |d 910000 |d 910100 |e 910000PR132951320 |e 910100PR132951320 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1687319804 |e 3575125503 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"note":["Gesehen am 14.01.2020"],"recId":"1687319804","id":{"doi":["10.1016/j.bbmt.2019.06.028"],"eki":["1687319804"]},"title":[{"title_sort":"Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors","title":"Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors","subtitle":"a retrospective study by the EBMT Chronic Malignancies Working Party"}],"relHost":[{"recId":"334374782","pubHistory":["Volume 4, issue 1 (June 1998)-Volume 26, issue 12 (December 2020)"],"titleAlt":[{"title":"BBMT"}],"note":["Gesehen am 16.03.2021"],"disp":"Allogeneic stem cell transplantation for blast crisis chronic myeloid leukemia in the era of tyrosine kinase inhibitors a retrospective study by the EBMT Chronic Malignancies Working PartyBiology of blood and marrow transplantation","id":{"zdb":["2057605-5"],"eki":["334374782"],"issn":["1523-6536"]},"title":[{"subtitle":"BBMT ; the official journal of the American Society for Blood and Marrow Transplantation","title":"Biology of blood and marrow transplantation","title_sort":"Biology of blood and marrow transplantation"}],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"[1998-2020]","publisherPlace":"[Erscheinungsort nicht ermittelbar] ; Charlottesville, Va.","publisher":"Elsevier Health Sciences ; Carden Jennings"}],"part":{"text":"25(2019), 10, Seite 2008-2016","issue":"10","volume":"25","extent":"9","year":"2019","pages":"2008-2016"},"physDesc":[{"extent":"Online-Ressource"}]}],"person":[{"role":"aut","display":"Radujković, Aleksandar","given":"Aleksandar","family":"Radujković","roleDisplay":"VerfasserIn"},{"given":"Sascha","display":"Dietrich, Sascha","role":"aut","family":"Dietrich","roleDisplay":"VerfasserIn"},{"given":"Henric-Jan","display":"Blok, Henric-Jan","role":"aut","family":"Blok","roleDisplay":"VerfasserIn"}],"name":{"displayForm":["Aleksandar Radujkovic, Sascha Dietrich, Henric-Jan Blok, Arnon Nagler, Francis Ayuk, Jürgen Finke, Johanna Tischer, Jiri Mayer, Yener Koc, Federica Sorà, Jakob Passweg, Jenny L. Byrne, Pavel Jindra, Joan Hendrik Veelken, Gerard Socié, Johan Maertens, Nicolaas Schaap, Michael Stadler, Maija Itälä-Remes, Eleni Tholouli, Mutlu Arat, Vanderson Rocha, Per Ljungman, Ibrahim Yakoub-Agha, Nicolaus Kröger, Yves Chalandon"]},"physDesc":[{"extent":"9 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedDisp":"1 July 2019","dateIssuedKey":"2019"}],"language":["eng"]} | ||
| SRT | |a RADUJKOVICALLOGENEIC1201 | ||